Table of contents
- Trial overview
- Who was studied
- What was measured
- Study design and phase
- What the trial was trying to learn
- Key terms explained
Trial overview
The clinical trial for GSKVX000000034792 was a vaccine study in healthy younger and older adults.[1] It was designed to find and confirm the dose and to assess safety, reactogenicity, and immune response.[1]
The study looked at prevention of influenza infection, which means it focused on helping the body build protection against the flu before infection happens.[1]
Who was studied
The trial included healthy volunteers, split into younger and older adults.[1] This matters because immune responses can be different in different age groups, so the study could compare how well the vaccine worked across ages.[1]
The study was not focused on people who already had influenza. It was aimed at prevention in people who were healthy at the time of vaccination.[1]
Study design and phase
This was an interventional study, which means researchers gave the study vaccine and then observed what happened.[1] The phase was Phase 1/2, an early stage of clinical testing that combines safety and dose finding with early immune response testing.[1]
The trial was completed and enrolled 1272 participants.[1] The study also included comparison vaccines, which helped researchers compare the immune response and safety profile across different study groups.[1]
What was measured
The main outcomes focused on safety and reactogenicity.[1] The study measured local events at the injection site and systemic events in the body from Day 1 to Day 7.[1]
It also measured unsolicited adverse events from Day 1 to Day 28, serious adverse events from Day 1 to Day 183, adverse events of special interest from Day 1 to Day 183, and medically attended events from Day 1 to Day 183.[1] In Phase 1 only, the study checked for changes in laboratory values from normal to clinically significant abnormal results after vaccination.[1]
For immune response, the trial measured geometric mean titer (GMT), geometric mean increase, seroconversion rate, and whether antibody levels reached a set cut-off value for two antigens at Day 29.[1] These measures help show whether the vaccine triggered the body to make antibodies against the flu antigens.[1]
What the trial was trying to learn
The brief summary shows two main goals: to evaluate the safety and reactogenicity profile of the investigational study intervention, and to evaluate the humoral immune response.[1] Humoral immune response means the part of the immune system that makes antibodies in the blood.[1]
Because the study was in healthy adults, the results are most useful for understanding how the vaccine performs in people without current influenza illness.[1] The trial data do not provide a treatment claim for sick patients; they describe a prevention-focused vaccine study.[1]
Key terms explained
Solicited events are symptoms or reactions that researchers ask participants about on purpose, usually soon after vaccination.[1] Unsolicited adverse events are any other unwanted medical problems that participants report during the study period.[1]
Serious adverse events are medical problems that are more severe, such as those that are life-threatening or need hospital care.[1] Medically attended events are problems that lead a participant to seek medical care.[1]
Antigen means a part of the vaccine or virus that the immune system recognizes and responds to.[1] Seroconversion means a change in blood test results that shows a new antibody response after vaccination.[1]
